IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) today announced that its wholly owned subsidiary, IntelGenx Corp., a leader in pharmaceutical films, has agreed to the terms of a strategic partnership with atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, including an equity investment by atai, pursuant to which atai will initially acquire an approximate 25% interest in the Corporation. The Corporation also announced that atai has granted to IntelGenx a secured loan in the amount of US$2,000,000.
atai Life Sciences Announces Strategic Partnership with IntelGenx
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a…
JOIN THE ATAI #INSIGHTNETWORK